Patent ID: 6929918

Claim:
Method of analyzing PSA (prostate specific antigen) protein ratios present in a blood, serum, urine or seminal fluid sample of a male patient, for the purpose of diagnosing an adenocarcinoma of the prostate or a benign prostate hyperplasia (BPH), said method comprising: measuring a level of total free PSA in the sample, wherein the total free PSA consists of cleaved and non-cleaved free PSA, measuring the level of cleaved free PSA in the sample, calculating a patient ratio of the cleaved free PSA level relative to the total free PSA level, comparing the patient ratio to a reference value, wherein the reference value is a ratio of cleaved free PSA levels relative to total free PSA levels found in patients suffering from adenocarcinoma of the prostate, and wherein the reference value is between 2% and 12%, interpreting a patient ratio greater than the reference value as an indication that the patient has a benign prostate hyperplasia, and interpreting a patient ratio less than or equal to the reference value as an indication that the patient has an adenocarcinoma of the prostate.